Termine
Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 1 Woche 6 Tage
@MorphoSys
Today is #WorldCancerDay2020.
We are fueled by our mission to make exceptional, innovative biopharmaceuticals to i… https://t.co/cxdr0pzGOI
vor 1 Woche 6 Tage
@MorphoSys
20 years ago, #WorldCancerDay was established to acknowledge the impact of cancer on human life and society. Aiming… https://t.co/ezH7lKhrX6
vor 1 Monat 5 Tage
@MorphoSys
We are very happy to announce that today @MorphoSys and @Incyte have entered into a collaboration and license agre… https://t.co/wuLfppWikm
vor 2 Monate 2 Wochen
@MorphoSys
@MorphoSys is looking forward to be at #ASH2019 in Orlando – come and visit us at booth #1261
View our abstracts ac… https://t.co/8frQalvXlh
vor 3 Monate 1 Tag
@MorphoSys
@MorphoSys today announced that tafasitamab B-MIND DLBCL study successfully passed interim analysis… https://t.co/GKEruipifQ
vor 4 Monate 3 Tage
@MorphoSys
@MorphoSys today takes part at #LightTheNight in Boston organized by @LLSusa to help fund treatments that are savin… https://t.co/kdwPTbD1F0
vor 4 Monate 1 Woche
@MorphoSys
“Thank you @JohnCendpts for moderating this great panel on ‘Cancer Drug Trials’ and for having me as speaker. It wa… https://t.co/yZU8hgcDUa
vor 4 Monate 2 Wochen
@MorphoSys
To maximise the value of our key asset #tafasitamab (MOR208) “We’ll do what makes sense for the patients and for ou… https://t.co/78POIo1yR5
vor 4 Monate 3 Wochen
@MorphoSys
Thank you #Berenberg & @GoldmanSachs. It was a great 8th German Corporate #Conference in #Munich.
Our new CEO Jean-… https://t.co/89oAuX5KuN
vor 5 Monate 4 Tage
@MorphoSys
#MorphoSys announced that the licensee @JanssenGlobal reported submission of a supplemental Biologics License Appl… https://t.co/zZTaX0tmGb
Investorenkontakt
Dr. Julia Neugebauer
Director Corporate Communications & Investor Relations
Telefon +49 89 89927 179
Medienkontakt
Dr. Anca Alexandru
Associate Director Corporate Communications & IR
Telefon +49 89 89927 26738
Dr.Verena Kupas
Associate Director Corporate Communications & Investor Relations
Telefon +49 89 89927 26814